Integration of PKPD relationships into benefit–risk analysis

E-ISSN： 1365-2125|80|5|979-991

ISSN： 0306-5251

Source： BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.80, Iss.5, 2015-11, pp. : 979-991

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A benefit–risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy

By Walker Anna Watson Crystal Alexopoulos Stamatia T. Deniz Baris Arnold Ryan Bates David

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 629-635

Informa Healthcare

Access to resources Recommend Favorite

Human papillomavirus vaccines: Understanding the benefit-risk

By Neels Pieter

Annals of Medicine, Vol. 45, Iss. 3, 2013-05 ,pp. : 203-205

Informa Healthcare

Access to resources Recommend Favorite

Benefit–risk assessment of vitamin D supplementation

By Bischoff-Ferrari H. Shao A. Dawson-Hughes B. Hathcock J. Giovannucci E. Willett W.

Osteoporosis International, Vol. 21, Iss. 7, 2010-07 ,pp. : 1121-1132

Springer Publishing Company

Access to resources Recommend Favorite

Benefit–risk management in the age of personalized healthcare

By Forstner Michael

Personalized Medicine, Vol. 9, Iss. 5, 2012-07 ,pp. : 507-514

Future Medicine

Access to resources Recommend Favorite

Inter‐study variability of preclinical in vivo safety studies and translational exposure–QTc relationships – a PKPD meta‐analysis

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 17, 2015-09 ,pp. : 4364-4379

John Wiley & Sons Inc

Access to resources Recommend Favorite